Physician profile
Brian Boone
NPI 1821309683
$1,621.31
in general payments reported to CMS, 2019-2025
13 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $533 · 2020: $329 · 2021: $406 · 2022: $114 · 2023: $14.71 · 2024: $62.01 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $239.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $494.34 | 2019-2021 | |
| Optinose US, INC. | $292.42 | 2019-2025 | |
| Medtronic USA, INC. | $268.25 | 2019-2020 | |
| Genzyme Corporation | $129.33 | 2019-2025 | |
| Novo Nordisk INC | $98.87 | 2019-2022 | |
| Amgen INC. | $91.18 | 2019 | |
| Medtronic, INC. | $84.26 | 2021 | |
| Glaxosmithkline, LLC. | $58.17 | 2023-2025 | Nucala |
| Novartis Pharmaceuticals Corporation | $35.94 | 2021 | |
| Lilly USA, LLC | $22.54 | 2025 | Zepbound |
| Genentech USA, INC. | $17.14 | 2019 | |
| Eisai INC. | $16.80 | 2020 | |
| Eyevance Pharmaceuticals LLC | $12.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Boone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.